ALX Oncology reported a reduced GAAP net loss of $25.9 million for Q2 2025, down from $39.4 million in the prior year, primarily due to lower R&D expenses. The company also extended its cash runway into Q1 2027 and made significant progress in its evorpacept and ALX2004 clinical programs.

ALX Oncology reported a net loss of $30.8 million for Q1 2025, an improvement from the $35.6 million net loss in Q1 2024, primarily due to lower R&D expenses. The company's cash runway has been extended into Q4 2026.

ALX Oncology announced topline data from its ASPEN-06 Phase 2 trial, showcasing evorpacept as the first CD47-blocking agent with durable clinical benefit and a well-tolerated safety profile in a randomized clinical trial. The company reported cash, cash equivalents, and investments of $162.6 million as of September 30, 2024, sufficient to fund planned operations well into Q1 2026.

ALX Oncology reported a GAAP net loss of $39.4 million for the second quarter of 2024, compared to a net loss of $34.2 million for the same period in 2023. Research and development expenses were $34.7 million, and general and administrative expenses were $6.9 million. Cash, cash equivalents, and investments totaled $186.2 million as of June 30, 2024.

ALX Oncology reported its Q1 2024 financial results, highlighting the progress of its lead product candidate, evorpacept, and its clinical trials. The company's cash, cash equivalents, and investments totaled $184.5 million as of March 31, 2024. R&D expenses were $31.7 million, and G&A expenses were $6.0 million. The GAAP net loss was $35.6 million, or ($0.71) per share, while the non-GAAP net loss was $28.5 million.

ALX Oncology reported a GAAP net loss of $45.5 million for Q4 2023, compared to a net loss of $30.7 million for Q4 2022. The company's cash, cash equivalents, and investments were $218.1 million as of December 31, 2023.

ALX Oncology reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatment of advanced HER2-positive gastric/gastroesophageal junction (GEJ) cancer, completed a public offering generating gross proceeds of approximately $63.2 million, and realigned its leadership team.

ALX Oncology reported its Q2 2023 financial results, highlighting the advancement of the ASPEN-06 trial and a strategic shift towards combinations with anti-cancer antibodies, ADCs, and PD-1/PD-L1 inhibitors. The company is terminating the ASPEN-02 and ASPEN-05 programs, reallocating resources to ongoing programs.

ALX Oncology reported a GAAP net loss of $30.2 million for the first quarter ended March 31, 2023, compared to a GAAP net loss of $24.5 million for the first quarter ended March 31, 2022. The company's cash, cash equivalents, and investments totaled $256.2 million as of March 31, 2023.

ALX Oncology reported its Q4 and full year 2022 financial results, highlighting the advancement of their lead program, evorpacept, into multiple solid tumor indications and hematological malignancies. They also expanded evorpacept into new indications and combinations. The company believes its cash, cash equivalents, investments and the ability to draw down up to an additional $40 million of its term loan are sufficient to fund planned operations through mid-2025.

ALX Oncology reported its Q3 2022 financial results, highlighting the expansion of the clinical development of evorpacept and a new non-dilutive term loan facility expected to extend the company's cash runway to mid-2025.

ALX Oncology reported a net loss of $32.9 million for the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $324.2 million as of June 30, 2022, which is expected to fund operations through the fourth quarter of 2024. The FDA granted Fast Track designation to evorpacept for HNSCC and Orphan Drug Designation for AML.

ALX Oncology reported a GAAP net loss of $24.5 million for the first quarter ended March 31, 2022, or $0.60 per basic and diluted share, as compared to a net loss of $14.2 million for the first quarter ended March 31, 2021, or $0.35 per basic and diluted share. Cash, cash equivalents and investments as of March 31, 2022 were $341.7 million.

ALX Oncology reported a GAAP net loss attributable to common stockholders of $28.4 million for the fourth quarter ended December 31, 2021, or $0.70 per basic and diluted share, as compared to a net loss of $18.8 million for the fourth quarter ended December 31, 2020, or $0.50 per basic and diluted share. Cash and cash equivalents as of December 31, 2021 were $363.7 million.

ALX Oncology reported its Q3 2021 financial results, highlighting the advancement of its lead program, evorpacept (ALX148), through multiple clinical trials, including new data from the ASPEN-01 trial presented at the ESMO conference and the dosing of the first patient in the ASPEN-04 trial. The company also acquired ScalmiBio, expanding its immuno-oncology pipeline.

ALX Oncology reported a net loss of $27.5 million for the second quarter of 2021. The company is focused on advancing its clinical programs, particularly ALX148, and reported positive data updates. ALX Oncology ended the quarter with a strong cash balance of $328.1 million.

ALX Oncology reported a net loss of $18.8 million for the fourth quarter ended December 31, 2020. The company's cash and cash equivalents were $434.2 million as of December 31, 2020, which is expected to fund operations through 2024.

ALX Oncology reported its third quarter 2020 financial results, highlighting progress in advancing ALX148 in clinical trials, securing a clinical trial collaboration with Merck, and presenting encouraging data from the ASPEN-01 Phase 1b Study.

ALX Oncology reported second quarter financial results, highlighting the completion of their initial public offering in July 2020, which raised gross proceeds of $185.7 million. The company's lead development candidate, ALX148, is advancing in multiple clinical trials, and the company believes its cash balance is sufficient to fund planned operations through 2023.